Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

602 results about "Keratinocyte" patented technology

Keratinocytes constitute 90% of the cells of the epidermis, the outermost layer of the skin. When found in the basal layer (stratum basale) of the skin, they are sometimes referred to as basal cells or basal keratinocytes.

Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer

This invention relates to a transdermal delivery system for treating skin related diseases employing protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of non-melanoma skin cancer. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.
Owner:AURA BIOSCI

Compositions and methods for skin care

Compositions and methods are for disclosed for treating a skin condition that results from reactive oxygen species production in skin of a subject, including applying a topical formulation that contains a lipophilic cation-mitochondrially targeted antioxidant compound and that delivers a therapeutically effective amount of the antioxidant compound to skin fibroblasts and keratinocytes.
Owner:ANTIPODEAN PHARMA

Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment of Alopecia

This invention relates to a transdermal delivery system for treating skin related diseases employing papilloma-derived protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of alopecia. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.
Owner:AURA BIOSCI

Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Dermatology Related Genetic Diseases

This invention relates to a transdermal delivery system for treating skin related genetic diseases. More specifically, the present invention provides particles and methods for using pseudo-viruses, including those derived from the herpes and papillomaviruses, to deliver drugs to keratinocytes and basal membrane cells for the treatment of skin genetic disorders including Pachyonychia Congenita and Xeroderma Pigmentosum.
Owner:AURA BIOSCI

Botulinum toxin in the treatment or prevention of acne

Botulinum toxin may be used to inhibit the cascade of events leading to acne. Results in preliminary studies have been dramatic. Withoout wishing to be bound by this theory, it is believed that botulinum toxin achieves this result through parasympathetic effects, inhibiting sweat gland activity, stimulating keratinocyte locomotion, anti-inflammatory effects, and possibly anti-androgenic effects. Botulinum toxin can play an important role in decreasing and even preventing the formation of acne.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE

Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators

ActiveUS20100028317A1Enhance cell viabilityPromote cellular longevityBiocideCosmetic preparationsPersonal careCircadian clock gene
Compositions and methods for enhancing repair of damaged DNA in skin cells. Topical compositions comprising at least one agent that upregulates circadian gene expression in skin cells and at least one non-circadian agent that delays mitosis in skin cells. Preferably, such compositions comprise one or more keratinocyte clock and per1 gene activators, along with SIRT1 or one or more sirt1 activators. More preferably, the sirt1 activator is a synergistic combination of specific peptidic sirt1 activators and resveratrol. Preferably, such compositions are easy to use, efficacious, cosmetically acceptable, chemically, thermodynamically and light stable, safe for topical use, have little or no side effects, and commercially feasible in a personal care marketplace.
Owner:ELC MANAGEMENT LLC

Tissue engineered biomimetic hair follicle graft

InactiveUS20050214344A1High degreeReduces and inhibits and cure lossBiocideAnimal repellantsBioabsorbable scaffoldAllogeneic cell
The present invention relates to an improved scaffold which is constructed to mimic the architecture of the native hair follicle. The present invention also relates to the use of specific compositions and methods of manufacture to produce scaffolds that combine biocompatibility with the desired rates of bioabsorption. In another embodiment, the present invention relates to a process for manufacturing a biomimetic hair follicle graft and a method for seeding the graft with cells and implanting the graft into the skin where the growth of a new hair shaft is desired. A further embodiment of the present invention relates to a method for hair multiplication in which cells are multiplied in culture and aliquoted into a multitude of bioabsorbable scaffolds in combination with cultured keratinocytes or other allogenic cells.
Owner:ADERANS RES INST

Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For the Treatment of Psoriasis

This invention relates to a transdermal delivery system for treating skin related diseases employing protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of Psoriasis. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.
Owner:AURA BIOSCI

Skin Care Compositions and Treatments

The invention is directed compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents are collected and incorporated into pharmaceutical or cosmetic preparations to treat an individual. The preparation is applied and has a rejuvenating effect on the cells and tissue.
Owner:ORGANOGENESIS

Tocopherol esters and their cosmetic and pharmaceutical uses

PCT No. PCT / FR98 / 00958 Sec. 371 Date Nov. 10, 1999 Sec. 102(e) Date Nov. 10, 1999 PCT Filed May 14, 1998 PCT Pub. No. WO98 / 51679 PCT Pub. Date Nov. 19, 1998The invention relates to an ester. The ester is characterized in that it presents the following chemical formula (I): in which: R1, R2 and R3 independently represent an atom of hydrogen, a methyl radical, A represents the following groups: R4 and R5 are identical or different and each represents a chain of the form:-Bm-Cn-Bp-Cq-Hin which: B is the following group: C is the following group: and in which the indices m, n, p, and q are respective integers lying in the range 0 to 4, it being understood that the sum m+n+p+q is limited to integers in the range 0 to 4. The ester can be used for preparing cosmetic or pharmaceutical, in particular dermatological, compositions having activity against radicals, against inflammation, favoring differentiation of keratinocytes, improving skin moisturizing, improving skin grain fineness, and having anti-aging or depigmenting activity.
Owner:LVMH RECH

C-glycoside compounds for stimulating the synthesis of glycosaminoglycans

C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and / or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and / or proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and / or keratinocytes.
Owner:LOREAL SA

Anti aging application and method for treating aging

There is a topical anti-aging composition which is configured to interfere with the production of tyrosinase, as well as melanin by reacting with melanocytes as well as reacting with, or acting on keratinocytes. The anti-aging composition comprises an emulsion comprising a plurality of active ingredients comprising a plurality of pigmentation reducing elements which are configured to interrupt or prevent the production of tyrosinase and melanin. In addition there are a plurality of antioxidants a plurality of anti wrinkling agents a plurality of anti-inflammatory agents at least one additional agent comprising at least one of an emollient, a proactant and a conditioning agent.
Owner:VASKIN

Skin substitutes with improved barrier function

The present invention relates to in vitro cultured skin substitutes, and in particular to in vitro cultured skin substitutes that have improved barrier function. In some embodiments, improved barrier function is a result of improved culture conditions, while in other embodiments, improved barrier function results from genetic modification of keratinocytes. Improved culture conditions to improve barrier function include organotypic culture in the presence of linoleic acid and / or linoleic acid at about 75% humidity. Suitable genetic modifications for improving barrier function includes transfection with a DNA construct capable of expressing GKLF.
Owner:STRATATECH

Beta-endorphin activity in cosmetics and dermatology

The subject of the invention is the use of at least one compound chosen from β-endorphin and β-endorphin-mimetic agents on the keratinocytes of the skin, for example in a cosmetic composition to enhance the barrier function of the skin, enhance its resistance to stress and in particular to pollution. It also relates to a method of cosmetic treatment for enhancing the barrier function and / or the moisturization of the skin and / or mucous membranes.
Owner:LOREAL SA

Skin care compositions and treatments

The invention is directed to compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents are collected and incorporated into pharmaceutical or cosmetic preparations to treat an individual. The preparation is applied and has a rejuvenating effect on the cells and tissue.
Owner:ORGANOGENESIS

Sustained-release oral ulcer film having biological adhesion and preparation method of sustained-release oral ulcer film

The invention relates to a sustained-release oral ulcer film having biological adhesion and a preparation method of the sustained-release oral ulcer film. According to the formula, the sustained-release oral ulcer film having the biological adhesion consists of the following components in percentage by weight: 5-50% of a bio-adhesion material, 5-80% of a sustained-release film forming material, 0.5-10% of a medicine, 1-50% of a supporting agent, 1-20% of a plasticizer, 0.1-0.5% of a bacteriostatic agent and 0.5-1% of a flavoring agent. The film provided by the invention, which is prepared in a specific production mode, is good in stability, and excellent biological adhesion and sustained-release performance of the film can be kept for a long time; a soluble sustained-release gel can be gradually formed as the film is adhered to an ulcer surface and absorbs water, so that contact of the ulcer surface with external side is prevented; the oral ulcer film provided by the invention has the characteristics of diminishing inflammation, alleviating pain, achieving an antibacterial effect and being free from toxins, irritation, mutagenic action and the like; and the oral ulcer film can promote growth of blood vessel endothelium and proliferation of fibroblasts and keratinocytes, and subsequently, the oral ulcer film can promote regeneration, repair of healing of the ulcer surface.
Owner:HARBIN QIANBAINA BIOPHARM

Novel C-glycosides, uses thereof

The present invention relates to novel C-glycoside compounds of given absolute configuration, to a process for synthesising them and to compositions containing them. The invention also relates to the cosmetic use of these C-glycoside compounds as agents to stimulate the synthesis of glycosaminoglycans containing a D-glucosamine and / or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and / or of proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and / or keratinocytes. The invention also relates to a cosmetic process for treating keratin materials using a composition containing at least one C-glycoside compound according to the invention.
Owner:LOREAL SA

External preparation for skin moistening

The invention relates to an external preparation for skin moistening. The preparation is formed by an effective component and medically acceptable auxiliary materials, and is characterized in that the effective component is dendrobium officinale polysaccharide with the molecular weight of 85-90 KDa. The external preparation for skin moistening disclosed by the invention can increase the expression quantity of a skin aquaporins-3 gene so as to accelerate further multiplication of malpighian cells and obviously improve a skin water retention effect.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Pigment-containing artificial skin detection model and preparation method thereof

The invention relates to a pigment-containing artificial skin detection model and a preparation method thereof. The artificial skin detection model is an epidermal layer structure with activity, which is constructed by compositely inoculating cutin formative cells and melanophores to the surface of a support membrane made from a biodegradable material through culture and comprises a stratum basale, a stratum spinosum, a stratum granulosum and a stratum corneum, and a basilar membrane structure is formed between the epidermal layer and the biodegradable material positioned below the epidermal layer. Compared with the conventional product, the invention can better simulate the pigment components of natural skin and more accurately reflect the whitening and sunscreen effect of cosmetics because of containing the melanophores, nourish the cutin formative cells by using the support membrane made from the biodegradable material as an enderonic layer, control the contraction of the epidermal layer with the strength and enhance the stability of the detection model and has low raw material cost, short manufacturing period and mass production; and in addition, the prepared artificial skin detection model can be directly used for the efficacy detection of the cosmetics and the skin irritation detection of textiles, the cosmetics and chemicals.
Owner:GUANGDONG BOXI BIO TECH CO LTD

Stem cell preparation for repairing skin ulcer

The invention relates to a stem cell preparation for repairing skin ulcer. The stem cell preparation consists of mesenchymal stem cells and exogenous cell factors. The stem cell preparation is prepared from the mesenchymal stem cells in combination with the exogenous cell factors, so that the directional differentiation of the mesenchymal stem cells towards endothelial cells is promoted; and through the paracrine of the mesenchymal stem cells as well as the exogenous cell factors, the growth of the endothelial cells is stimulated, fibroblast and capillary growth as well as collagen synthesis and granulation in a wound surface are enhanced, and the proliferation of skin keratinocytes and endothelial cells is improved, so that the purpose of rapidly and effectively repairing skin with ulcer injury is achieved.
Owner:SHEN ZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD

Culture method of hair follicle stem cell for treating baldness, as well as syringe

The invention relates to the field of health-care, and in particular relates to a culture method of hair follicle stem cell for treating baldness, as well as a syringe. The culture method comprises the following steps: A, digesting excised hair follicles by utilizing separase; B, cutting bugle of follicles; C, digesting the follicle bugle by utilizing pancreatin; D, centrifugally collecting the follicle bulge obtained in the step C to obtain cells; E, culturing the cells in DEME (Dulbecco's Modified Eagle's Medium) culture solution, and primarily separating; F, culturing the product which is obtained in primary separation of the step E in a culture dish; and G, centrifugally collecting upper unattached keratinocyte and follicle fibroblast which are cultured in the step F, and culturing to obtain hair follicle stem cells. The syringe comprises a hair follicle stem cell extraction component and a syringe needle, wherein the hair follicle stem cell extraction component is used for quantitatively extracting hair follicle stem cells, and connected with the syringe needle; and the syringe needle is bent and blunt. According to the method and the syringe, hair growth under baldness situation can be improved.
Owner:北京雍禾植发技术研究院有限公司

Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures

Provided herein are methods for the generation of functional keratinocyte stem cells that are differentiated directly from human ESCs / iPSCs in a chemically defined serum-free cell culture system, as well as cells derived therefrom and methods of use thereof. Also provided are methods for culturing primary keratinocytes.
Owner:FUJIFILM CELLULAR DYNAMICS INC

Pellets obtained from cell cultures of keratinocytes and their use in wound healing

PCT No. PCT / EP92 / 02657 Sec. 371 Date Aug. 22, 1994 Sec. 102(e) Date Aug. 22, 1994 PCT Filed Nov. 19, 1992 PCT Pub. No. WO93 / 10217 PCT Pub. Date May 27, 1993The present invention relates to a process for treating a skin surface wound of a human. The process includes topically applying a keratinocyte pellet fraction onto the wound to result in wound closure. The invention also relates to a pharmaceutical composition including a pharmaceutically acceptable vehicle and a keratinocyte pellet fraction. The keratinocyte pellet fraction can be produced in a sterile manner by growing a keratinocyte culture, lysing the keratinocytes, centrifugation, and recovering the keratinocyte pellet fraction.
Owner:CELLTRAN LTD

Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders

InactiveUS20030194456A1Safe and well-toleratedMinimal effectBiocideAntipyreticPhosphodiesteraseEnzyme inhibition
The invention provides a novel herbal composition containing the extracts of the leaves and / or stem of <italic>Argemone mexicana < / highlight>plant, optionally containing the extracts of the fruits of <italic>Cuminum cyminum< / highlight>, which exhibits useful in vitro, in vivo and interesting immunological and pharmacological activities; a process for preparation thereof; and a method of treatment of psoriasis and related immunological and biological disorders by administration of the said novel herbal composition. The useful in vitro, in vivo and interesting immunological and pharmacological activities exhibited by the extracts and fractions of the leaves and / or stem of <italic>Argemone mexicana < / highlight>plant include immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFNgamma inhibition, IL-10 induction, keratinocyte proliferation inhibition, keratolytic activity, endothelial cell proliferation inhibition, inhibition of cell adhesion molecule expression such as ICAM-1, MEST inhibition, and enzymes inhibition such as p60src Tyrosine kinase, which are known to be involved in anti-psoriatic activity. The novel herbal composition(s) is useful in the treatment of various disorders, such as psoriasis including plaque psoriasis, gutatte psoriasis, pustular psoriasis and psoriasis of the nails; dermatitis and scleroderma; eczema; inflammatory disorders and other autoimmune diseases like psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, irritable bowel disease, ankylosing spondilitis, systemic lupus erythremetosus and Sjogren's syndrome; allergies like asthma and chronic obstructive pulmonary disease and is safe, well-tolerated, non-toxic, with minimal and reversible adverse reactions or side effects, and most importantly, with minimal relapse or recurrence of the disease following completion of a treatment regimen. The invention also describes the presence of phosphodiesterase (III, IV and V) inhibition and 5-Lipoxygenase inhibition in the aqueous, ethanolic or aqueous-ethanolic extracts of fruits of <italic>Cuminum cyminum < / highlight>plant.
Owner:LUPIN LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products